Our onco-metabolism approach brings
an enhanced perspective to cancer.
- Company
- About Us
- Management Team
- Board of Directors
- Collaborations
- Careers
- Contact Us
- Science
- Onco-Metabolism Platform
- Therapeutic Areas
- Publications
- Programs
- Pipeline
- Glutaminase Inhibitor Telaglenastat
- Arginase Inhibitor INCB001158
- Arginase Inhibitor
CB-280 - CD73 Inhibitor
CB-708 - Clinical Trials
- Clinical Trials Overview
- Expanded Access
- Media & Investors
- Corporate Profile
- Press Releases
- Event & Presentations
- Stock Information
- Financial Information
- Overview
- SEC Filings
- Ownership Summary
- Analyst Coverage
- Corporate Governance
- Highlights
- Board of Directors
- Management Team
- Committee Composition
- Shareholder Services
-
Data from Investigator-Sponsored Phase 2 Study of Calithera’s Telaglenastat with Azacitidine in Myelodysplastic Syndrome to be Presented at ASH Annual Meeting 2019
-
Calithera Biosciences Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Calithera Biosciences Reports Third Quarter 2019 Financial Results and Recent Highlights
-
Calithera to Present Preclinical Data from IL4I1 and CD73 Programs at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
-
Calithera Biosciences to Report Third Quarter 2019 Financial Results on Tuesday, November 12, 2019
Targeting cancer, differently.
Targeting cancer, differently.
Our onco-metabolism approach brings
an enhanced perspective to cancer.Targeting cancer, differently.
Our onco-metabolism approach brings
an enhanced perspective to cancer.Development Pipeline
Calithera is pioneering the discovery and development of targeted, small molecule therapies that disrupt cellular metabolic pathways to preferentially block tumor cell growth and enhance immune-cell activity.
Development Pipeline
Calithera is a clinical-stage biopharmaceutical company pioneering the discovery and development of targeted, small molecule therapies that disrupt cellular metabolic pathways to preferentially block tumor cell growth and enhance immune-cell activity.
Recent News